Chemotherapy induced Neuropathy.
Conditions
Interventions
Intervention 1: Intervention group: Prescription of coenzyme Q10 for the prevention and treatment of chemotherapy-induced neuropathy. Intervention 2: Control group: Administration of a placebo, identi
Sponsors
Hamedan University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Adult women aged 18 to 65 years No history of chemotherapy Histological confirmation of breast cancer Non-metastatic status confirmed by paraclinical findings, including CT scan, bone scan, or PET-CT scan ECOG-PS: 0-2 No history of diabetes or other underlying neuropathic conditions
Exclusion criteria
Exclusion criteria: Prior administration of chemotherapeutic agents ECOG-PS: 3-4 Co-administration of Warfarin pregnancy Hypersensitivity to supplements containing Coenzyme Q10
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence and severity of neuropathy,. Timepoint: Before and One week after completion of chemotherapy. Method of measurement: NCI-CTCAE Version 5.0 and Electrodiagnostic tests including nerve conduction velocity, SNAP amplitude? SNAP latency. | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of Life (QoL). Timepoint: Before treatment, during treatment q3 weeks and after the end of treatment. Method of measurement: EORTC-QLQ-CIPN20 questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactKamal Mohammadian
Hamedan University of Medical Sciences
Outcome results
None listed